Mucosis Signs Research and License Option Agreement with Crucell

Groningen, the Netherlands, Oct 8, 2012 / B3C newswire / – Mucosis BV, a clin­i­cal-stage Dutch biotech­nol­o­gy com­pa­ny devel­op­ing inno­v­a­tive mucos­al vac­cines, today announced that it has signed a Research and License Option Agreement with Crucell Holland B.V. (“Crucell”), the Dutch devel­op­er of vac­cines and anti­bod­ies. Crucell is one of the Pharmaceutical Companies of Johnson & Johnson.
In the research col­lab­o­ra­tion, Crucell will make use of Mucosis’s pro­pri­etary Mimopath® plat­form tech­nol­o­gy and know-how in Crucell’s pro­gram for devel­op­ing undis­closed nov­el vac­cines to com­bat infec­tious dis­eases. Under the terms of the agree­ment, Mucosis will receive upfront pay­ments and could receive addi­tion­al pay­ments on the achieve­ment of agreed upon mile­stones. Financial details of the agree­ment were not dis­closed.
“We are delight­ed to col­lab­o­rate with Crucell as we strong­ly believe that our Mimopath® plat­form com­bined with Crucell’s exper­tise in vac­cine devel­op­ment cre­ate a sub­stan­tial oppor­tu­ni­ty to devel­op dif­fer­en­ti­at­ed and med­ical­ly rel­e­vant vac­cine can­di­dates”, said Thomas Johnston, CEO of Mucosis. “We are proud of the progress we’ve made to date in devel­op­ing the Mimopath® plat­form, includ­ing our recent pos­i­tive human clin­i­cal tri­als. We see this agree­ment as a fur­ther val­i­da­tion of our plat­form and its poten­tial to com­bat infec­tious dis­eases.”

Leave a Reply

Your email address will not be published. Required fields are marked *